Charles River Laboratories International, Inc. Share Price CBOE
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
CBOE
20:59:50 21/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 295.33 USD | +1.32% |
|
+3.67% | +45.99% |
| 08-20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| 08-20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
| Market Cap | 13.91B 11.91B 11.14B 10.2B 19.15B 1,331B 19.41B 132B 51.32B 668B 52.24B 51.1B 2,210B | P/E 2026 * |
78x | P/E 2027 * | 31.2x |
|---|---|---|---|---|---|
| Enterprise Value | 16.03B 13.72B 12.83B 11.75B 22.06B 1,533B 22.35B 152B 59.11B 770B 60.17B 58.85B 2,546B | EV / Sales 2026 * |
4.1x | EV / Sales 2027 * | 3.89x |
| Free-Float |
95.58% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Charles River Laboratories International, Inc.
| 1 week | +5.47% | ||
| Current month | +26.98% | ||
| 1 month | +34.62% | ||
| 3 months | +85.91% | ||
| 6 months | +74.73% | ||
| Current year | +47.92% |
| 1 week | 279.09 | 299.22 | |
| 1 month | 216.99 | 299.22 | |
| 3 years | 91.87 | 299.22 | |
| 5 years | 91.87 | 460 | |
| 10 years | 67.23 | 460 |
| Manager | Title | Age | Since |
|---|---|---|---|
Birgit Girshick
CEO | Chief Executive Officer | 56 | 04/05/2026 |
Glenn Coleman
DFI | Director of Finance/CFO | 58 | 05/04/2026 |
Namandje Bumpus
CTO | Chief Tech/Sci/R&D Officer | 45 | 11/01/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
James Foster
CHM | Chairman | 75 | 31/12/1999 |
Birgit Girshick
BRD | Director/Board Member | 56 | 04/05/2026 |
Martin MacKay
CHM | Chairman | 69 | 04/05/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.32% | +3.67% | +91.05% | +46.88% | 13.91B | ||
| +1.09% | +3.39% | +3.50% | +25.49% | 51.22B | ||
| -1.07% | +3.69% | +479.26% | +607.16% | 45.38B | ||
| +1.44% | +5.19% | +21.06% | +93.98% | 41.97B | ||
| +1.47% | +7.58% | +35.29% | +21.42% | 42.15B | ||
| -0.93% | -4.80% | +17.39% | +46.60% | 31.95B | ||
| -0.60% | +2.87% | - | - | 16.73B | ||
| +1.32% | +6.67% | +33.29% | +148.62% | 17.1B | ||
| +0.03% | +3.91% | +5.84% | +35.04% | 14.76B | ||
| +1.28% | +4.95% | +84.98% | +48.41% | 13.91B | ||
| Average | +0.45% | +3.19% | +85.74% | +119.29% | 30.58B | |
| Weighted average by Cap. | +0.48% | +3.13% | +102.66% | +145.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.91B 3.35B 3.13B 2.87B 5.38B 374B 5.46B 37.01B 14.42B 188B 14.68B 14.36B 621B | 4B 3.43B 3.2B 2.93B 5.51B 383B 5.58B 37.86B 14.76B 192B 15.02B 14.69B 636B |
| Net income | 162M 139M 130M 119M 223M 15.53B 226M 1.54B 599M 7.8B 610M 596M 25.79B | 428M 366M 343M 314M 589M 40.92B 597M 4.05B 1.58B 20.54B 1.61B 1.57B 67.94B |
| Net Debt | 2.11B 1.81B 1.69B 1.55B 2.91B 202B 2.95B 19.99B 7.79B 101B 7.93B 7.76B 336B | 1.63B 1.4B 1.31B 1.2B 2.24B 156B 2.27B 15.43B 6.01B 78.33B 6.12B 5.99B 259B |
| Date | Price | Change |
|---|---|---|
| 21/08/26 | US$295.33 | +1.32% |
| 20/08/26 | US$291.48 | +0.58% |
| 19/08/26 | US$289.80 | +3.84% |
| 18/08/26 | US$279.09 | -2.63% |
| 17/08/26 | US$286.63 | +2.36% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CRL Stock
- CRL Stock
Select your edition
All financial news and data tailored to specific country editions

















